AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2019
12/30/2018
12/30/2017
12/30/2016
Total Revenue
16,088,900
-
15,787,400
15,940,700
14,570,600
Cost of Revenue
2,493,100
-
2,191,400
2,168,000
1,860,800
Gross Profit
13,595,800
-
13,596,000
13,772,700
12,709,800
Operating Expenses
Research Development
1,812,000
-
2,266,200
2,100,100
2,575,700
Selling General and Administrative
5,943,500
-
4,521,800
5,016,700
4,740,300
Total Operating Expenses
13,612,100
-
13,340,300
14,313,900
13,786,400
Operating Income or Loss
-16,300
-
255,700
-541,200
-1,076,600
Interest Expense
783,000
-
911,200
1,095,600
1,295,600
Total Other Income/Expenses Net
-4,396,200
-
-6,246,600
-8,817,300
-529,700
Income Before Tax
-5,118,700
-
-6,856,900
-10,386,400
-2,832,000
Income Tax Expense
146,400
-
-1,770,700
-6,670,400
-1,897,000
Income from Continuing Operations
-5,265,100
-
-5,086,200
-3,716,000
-935,000
Net Income
-5,271,000
-
-5,096,400
-4,125,500
14,973,400
Net Income available to common shareholders
-5,271,000
-
-5,142,800
-4,403,900
14,695,000
Reported EPS
Basic
-
-16.02
-15.26
-13.19
38.18
Diluted
-
-16.02
-15.26
-13.19
38.18
Weighted average shares outstanding
Basic
-
329,000
337,000
333,800
384,900
Diluted
-
329,000
337,000
333,800
384,900
EBITDA
-
-
802,900
-1,922,200
5,094,600